


ABSTRACT

5 The invention relates to novel compounds having formula  
(I)



(I)

10 wherein Cy, X, Y, L and R<sub>1-6</sub> are as defined herein. The  
compounds bind CD11/CD18 adhesion receptors such as  
Lymphocyte Function-associated Antigen-1 (LFA-1) and are  
therefore useful for treating disorders mediated by LFA-  
1 such as inflammation and autoimmune diseases.